Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chinook Therapeutics (Nasdaq: KDNY) has announced the approval of a new employment inducement grant of stock options for a new employee, totaling 25,733 shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chinook Therapeutics (Nasdaq: KDNY) has announced the approval of a new employment inducement grant of stock options for a new employee, totaling 25,733 shares. The options have an exercise price of $14.12, equal to the closing price on June 30, 2021, and vest over four years. This grant follows Nasdaq Rule 5635(c)(4) and aims to attract talent to the company, which focuses on precision medicines for kidney diseases. Chinook is advancing its clinical programs, including atrasentan and BION-1301, targeting rare kidney disorders.
Positive
- The new employment inducement grant of stock options aims to attract talent, potentially enhancing company capabilities.
- Chinook is advancing multiple promising clinical programs for kidney diseases, showing commitment to innovative therapies.
Negative
- None.
Details
News Market Reaction – KDNY
The recorded move for KDNY in the trading session of this news was +3.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase 25,733 shares of common stock with a grant date of June 30, 2021 (the “Inducement Grants”) for a new employee.
The stock options approved under the Inducement Grant were issued on terms substantially similar to Chinook’s 2015 Equity Incentive Plan and have an exercise price per share equal to
The Company granted the stock options as a material inducement to this employee for entering into employment with Chinook Therapeutics, Inc. in accordance with Nasdaq listing Rule 5635(c)(4).
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
media@chinooktx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.